SUPN

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.01
Percentage change 0.03	%

Peers: NBIX ACAD TEVA UTHR INSM AXNX PTCT DRRX MNKD XENE

| Held by: IJR CALF VTI IWM VB AVUV VBR VXF SPSM IWN

Scroll to Statements

Index	RUT	P/E	33.86	EPS (ttm)	1.07	Insider Own	4.24%	Shs Outstand	55.22M	Perf Week	-2.69%
Market Cap	2.00B	Forward P/E	19.10	EPS next Y	1.89	Insider Trans	-12.83%	Shs Float	52.88M	Perf Month	-4.24%
Income	59.71M	PEG	20.04	EPS next Q	0.50	Inst Own	110.45%	Short Float	12.21%	Perf Quarter	14.90%
Sales	651.97M	P/S	3.06	EPS this Y	21.50%	Inst Trans	2.91%	Short Ratio	18.47	Perf Half Y	39.17%
Book/sh	18.24	P/B	1.98	EPS next Y	-33.72%	ROA	4.54%	Short Interest	6.45M	Perf Year	31.24%
Cash/sh	7.30	P/C	4.95	EPS next 5Y	1.69%	ROE	6.22%	52W Range	25.53 - 39.37	Perf YTD	24.98%
Dividend Est.	-	P/FCF	11.61	EPS past 5Y	-59.02%	ROI	5.76%	52W High	-8.13%	Beta	0.90
Dividend TTM	-	Quick Ratio	1.98	Sales past 5Y	9.22%	Gross Margin	76.28%	52W Low	41.68%	ATR (14)	1.11
Dividend Ex-Date	-	Current Ratio	2.20	EPS Y/Y TTM	128.31%	Oper. Margin	11.16%	RSI (14)	49.81	Volatility	2.74% 3.01%
Employees	652	Debt/Eq	0.04	Sales Y/Y TTM	6.79%	Profit Margin	9.16%	Recom	2.00	Target Price	39.25
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	334.94%	Payout	0.00%	Rel Volume	1.13	Prev Close	36.16
Sales Surprise	11.66%	EPS Surprise	163.57%	Sales Q/Q	14.17%	Earnings	Nov 04 AMC	Avg Volume	349.42K	Price	36.17
SMA20	-0.71%	SMA50	2.74%	SMA200	14.13%	Trades		Volume	394,882	Change	0.03%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-11-24	Downgrade	Piper Sandler	Overweight → Neutral	$41 → $36
Jan-03-23	Resumed	Jefferies	Buy	$44 → $45
Dec-01-21	Resumed	Jefferies	Buy	$40 → $44
Apr-13-21	Upgrade	Jefferies	Hold → Buy	$25 → $40
Jun-16-20	Upgrade	Piper Sandler	Neutral → Overweight	$25 → $31
Jun-15-20	Resumed	Jefferies	Hold	$24
Nov-08-19	Downgrade	Berenberg	Buy → Hold
Nov-07-19	Downgrade	Stifel	Buy → Hold	$55 → $23
Nov-06-19	Downgrade	Jefferies	Buy → Hold	$46 → $23
Nov-12-18	Reiterated	B. Riley FBR	Buy	$68 → $65
Jan-18-18	Reiterated	B. Riley FBR, Inc.	Buy	$54
Dec-28-17	Reiterated	B. Riley FBR, Inc.	Buy	$50 → $54
Dec-04-17	Upgrade	Janney	Neutral → Buy
Nov-08-17	Upgrade	Stifel	Hold → Buy	$47
Oct-19-17	Initiated	FBR & Co.	Buy	$53
Sep-19-17	Downgrade	Stifel	Buy → Hold	$47
Jul-17-17	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-14-17	Initiated	Janney	Neutral
Jun-01-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-18-16	Downgrade	Piper Jaffray	Overweight → Neutral

Show Previous Ratings

Nov-26-24 05:00PM	Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-13-24 04:30PM	Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference (GlobeNewswire)
Nov-05-24 08:00AM	Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-04-24 08:00PM	Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
07:35PM	Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates (Zacks)
06:33PM	Loading…
06:33PM	Supernus: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Supernus Announces Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-31-24 04:10PM	Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 (GlobeNewswire)
Oct-21-24 04:25PM	Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-18-24 08:31PM	Supernus depression drug improved symptoms in two hours in Phase IIa study (Clinical Trials Arena)
Oct-17-24 04:05PM	Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder (GlobeNewswire)
Oct-10-24 05:12PM	Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder (GlobeNewswire)
Oct-09-24 05:07PM	Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Sep-24-24 07:30AM	Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree (GlobeNewswire)
Sep-19-24 04:30PM	Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit (GlobeNewswire)
10:50AM	Loading…
Sep-16-24 10:50AM	Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key Drug (Insider Monkey)
Sep-11-24 02:38PM	ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug (Benzinga) -7.20%
Aug-28-24 04:15PM	Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-19-24 07:00AM	Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA (GlobeNewswire)
Aug-09-24 09:55AM	Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect? (Zacks)
Aug-06-24 08:00PM	Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) +14.49%
06:45PM	Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates (Zacks)
05:36PM	Supernus: Q2 Earnings Snapshot (Associated Press Finance)
04:06PM	Supernus Announces Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 04:30PM	Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device (GlobeNewswire)
Jul-23-24 04:13PM	Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 (GlobeNewswire)
Jul-19-24 01:58PM	If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names (InvestorPlace)
May-30-24 04:25PM	Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-24-24 11:53AM	Do Options Traders Know Something About Supernus (SUPN) Stock We Don't? (Zacks)
May-23-24 04:05PM	Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy (GlobeNewswire)
01:38PM	Loading…
May-10-24 01:38PM	Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ... (GuruFocus.com)
May-09-24 04:05PM	Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures (GlobeNewswire)
11:56AM	Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:42AM	Supernus Pharmaceuticals Inc (SUPN) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-08-24 10:56PM	SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024 (InvestorPlace)
07:00PM	Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics (Zacks)
04:05PM	Supernus Announces First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 11:46AM	Supernus, M8 Pharmaceuticals Sign Licensing Deal for ADHD Drug Qelbree in Latin America (MT Newswires)
10:00AM	M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree (Viloxazine XR) in Latin America (PR Newswire)
09:15AM	Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
May-01-24 08:00AM	Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story (GlobeNewswire)
Apr-24-24 04:05PM	Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 (GlobeNewswire)
Apr-08-24 12:11PM	Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease (Benzinga) -6.32%
08:00AM	Supernus Provides Regulatory Update for SPN-830 (GlobeNewswire)
Mar-27-24 04:37PM	Corporate Insiders Are Selling These 10 Small-Cap Stocks (Insider Monkey)
Mar-06-24 04:30PM	Supernus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Feb-28-24 04:30PM	Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire)
09:19AM	Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:17AM	Q4 2023 Supernus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 07:30PM	Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
06:50PM	Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates (Zacks)
06:02PM	Supernus: Q4 Earnings Snapshot (Associated Press Finance)
05:00PM	Supernus Pharmaceuticals Inc (SUPN) Reports Robust Growth in Key Products for Full Year 2023 (GuruFocus.com)
04:05PM	Supernus Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 09:15AM	Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
Feb-20-24 10:00AM	Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-13-24 04:05PM	Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024 (GlobeNewswire)
Feb-05-24 08:30AM	Supernus Wins Infringement and Validity Case on Trokendi XR against Torrent (GlobeNewswire)
Dec-19-23 07:30AM	Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree (viloxazine) in Canada (GlobeNewswire)
Dec-14-23 07:43PM	Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential (InvestorPlace)
Nov-18-23 05:03AM	Insider Sell Alert: Director Frederick Hudson Sells 9,093 Shares of Supernus Pharmaceuticals ... (GuruFocus.com)
Nov-10-23 12:10PM	Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 09:54AM	Q3 2023 Supernus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +11.14%
Nov-08-23 07:30PM	Supernus (SUPN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:15PM	Supernus Pharmaceuticals (SUPN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:08PM	Supernus: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Supernus Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-07-23 04:30PM	Supernus to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-02-23 07:00AM	Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA (GlobeNewswire)
Nov-01-23 10:01AM	Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-25-23 04:15PM	Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023 (GlobeNewswire)
Oct-16-23 05:34PM	Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey (GlobeNewswire)
Oct-09-23 04:45PM	Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device (GlobeNewswire)
Sep-27-23 04:15PM	Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City (GlobeNewswire)
Sep-26-23 07:37PM	Supernus Pharmaceuticals (SUPN): A Hidden Gem in the Market? A Comprehensive Analysis of Its ... (GuruFocus.com)
Sep-09-23 08:00PM	Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms (GlobeNewswire)
Aug-31-23 05:30PM	Supernus to Participate in the Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-21-23 09:00AM	Bethany L. Sensenig Joins Supernus Board of Directors (GlobeNewswire)
Aug-08-23 08:30PM	Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics (Zacks) -7.23%
07:55PM	Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:40PM	Supernus: Q2 Earnings Snapshot (AP Finance)
04:17PM	Supernus Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)
Jul-25-23 06:36AM	Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals? (Simply Wall St.)
Jul-24-23 04:05PM	Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 8, 2023 (GlobeNewswire)
Jun-27-23 11:50AM	The five-year shareholder returns and company earnings persist lower as Supernus Pharmaceuticals (NASDAQ:SUPN) stock falls a further 9.4% in past week (Simply Wall St.)
Jun-21-23 08:00PM	SUPN: What does Argus have to say about SUPN? (Argus Research)
Jun-10-23 07:40AM	Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy (Motley Fool)
May-31-23 04:15PM	Supernus to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 08:39AM	Top Healthcare Stocks for May 2023 (Investopedia)
May-10-23 11:23AM	Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-09-23 08:30PM	Supernus (SUPN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:05PM	Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Beat Estimates (Zacks)
06:09PM	Supernus: Q1 Earnings Snapshot (AP Finance)
04:05PM	Supernus Announces First Quarter 2023 Financial Results (GlobeNewswire)
May-02-23 04:05PM	Supernus to Present at the Bank of America 2023 Health Care Conference (GlobeNewswire)
Apr-26-23 08:00PM	SUPN: What does Argus have to say about SUPN? (Argus Research)
Apr-25-23 04:15PM	Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023 (GlobeNewswire)
Apr-03-23 04:05PM	Supernus Announces Repayment of Convertible Notes (GlobeNewswire)

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Dec 03 '24	Option Exercise	24.77	21,495	532,361	22,424	Dec 04 04:36 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Dec 03 '24	Sale	36.68	21,495	788,437	9,679	Dec 04 04:36 PM
PADMANABH P BHATT	Officer	Dec 03 '24	Proposed Sale	37.31	21,495	801,978		Dec 03 04:31 PM
NEWHALL CHARLES W III	Director	Nov 11 '24	Option Exercise	9.13	20,000	182,600	140,975	Nov 12 04:15 PM
NEWHALL CHARLES W III	Director	Nov 11 '24	Sale	36.24	10,700	387,768	130,275	Nov 12 04:15 PM
Hudson Frederick M.	Director	Nov 08 '24	Sale	36.28	8,722	316,434	28,395	Nov 12 04:14 PM
GEMAYEL GEORGES	Director	Nov 08 '24	Option Exercise	11.46	10,787	123,619	24,102	Nov 12 04:13 PM
GEMAYEL GEORGES	Director	Nov 08 '24	Sale	36.30	10,787	391,568	13,315	Nov 12 04:13 PM
Khattar Jack A.	President, CEO	Nov 08 '24	Option Exercise	9.13	125,000	1,141,250	1,051,172	Nov 12 04:11 PM
Khattar Jack A.	President, CEO	Nov 08 '24	Sale	36.29	125,000	4,536,250	926,172	Nov 12 04:11 PM
CHARLES NEWHALL	Officer	Nov 11 '24	Proposed Sale	36.24	10,700	387,775		Nov 12 09:18 AM
JACK A KHATTAR	Officer	Nov 08 '24	Proposed Sale	36.29	125,000	4,535,850		Nov 08 05:00 PM
FREDERICK M HUDSON	Director	Nov 08 '24	Proposed Sale	36.28	8,722	316,476		Nov 08 04:33 PM
GEORGES GEMAYEL	Director	Nov 08 '24	Proposed Sale	36.30	10,787	391,536		Nov 08 04:19 PM
Mottola Frank	SVP, Quality, GMP, Ops, IT	Nov 07 '24	Option Exercise	9.13	15,000	136,950	23,200	Nov 08 04:13 PM
Mottola Frank	SVP, Quality, GMP, Ops, IT	Nov 07 '24	Sale	36.98	15,000	554,700	8,200	Nov 08 04:13 PM
GEMAYEL GEORGES	Director	Nov 07 '24	Option Exercise	11.46	14,213	162,881	27,528	Nov 08 04:11 PM
GEMAYEL GEORGES	Director	Nov 07 '24	Sale	36.62	14,213	520,480	13,315	Nov 08 04:11 PM
Khattar Jack A.	President, CEO	Nov 07 '24	Option Exercise	9.13	125,000	1,141,250	1,051,172	Nov 08 04:08 PM
Khattar Jack A.	President, CEO	Nov 07 '24	Sale	36.68	125,000	4,585,000	926,172	Nov 08 04:08 PM
JACK A KHATTAR	Officer	Nov 07 '24	Proposed Sale	36.68	125,000	4,584,600		Nov 07 04:59 PM
FRANK MOTTOLA	Officer	Nov 07 '24	Proposed Sale	36.98	15,000	554,692		Nov 07 04:55 PM
GEORGES GEMAYEL	Director	Nov 07 '24	Proposed Sale	36.62	14,213	520,511		Nov 07 04:42 PM
GEMAYEL GEORGES	Director	Sep 13 '24	Option Exercise	11.46	10,000	114,600	23,315	Sep 17 04:10 PM
GEMAYEL GEORGES	Director	Sep 13 '24	Sale	31.33	13,886	435,048	13,315	Sep 17 04:10 PM
GEORGES GEMAYEL	Director	Sep 13 '24	Proposed Sale	31.33	13,886	435,041		Sep 13 04:30 PM
Khattar Jack A.	President, CEO	Sep 03 '24	Option Exercise	0.00	21,000	0	936,217	Sep 03 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Aug 20 '24	Option Exercise	0.00	1,250	0	10,251	Aug 20 05:00 PM
TAMI TILLOTSON MARTIN	Former Officer	Aug 02 '24	Proposed Sale	29.02	4,000	116,074		Aug 02 04:16 PM
TAMI TILLOTSON MARTIN	Former Officer	Aug 01 '24	Proposed Sale	29.31	3,100	90,856		Aug 01 04:19 PM
TAMI TILLOTSON MARTIN	Former Officer	Jul 31 '24	Proposed Sale	30.13	5,000	150,650		Jul 31 04:41 PM
TAMI TILLOTSON MARTIN	Former Officer	Jul 30 '24	Proposed Sale	30.56	2,900	88,610		Jul 30 04:02 PM
TAMI TILLOTSON MARTIN	Former Officer	Jul 29 '24	Proposed Sale	30.75	5,000	153,750		Jul 29 04:08 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 21 '24	Option Exercise	25.30	14,491	366,622	23,061	Mar 25 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 21 '24	Sale	35.31	14,491	511,677	8,570	Mar 25 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 20 '24	Option Exercise	25.30	400	10,120	8,970	Mar 22 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 20 '24	Sale	35.31	400	14,124	8,570	Mar 22 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 19 '24	Option Exercise	25.30	12,364	312,809	20,934	Mar 21 05:01 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 19 '24	Sale	35.31	12,364	436,573	8,570	Mar 21 05:01 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 13 '24	Option Exercise	17.61	62,366	1,098,523	44,686	Mar 15 06:39 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 13 '24	Sale	33.74	62,366	2,104,289	8,570	Mar 15 06:39 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 12 '24	Option Exercise	12.98	3,884	50,414	12,454	Mar 14 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 12 '24	Sale	32.99	3,884	128,133	8,570	Mar 14 05:00 PM
Mottola Frank	SVP, Quality, GMP, Ops, IT	Feb 28 '24	Option Exercise	0.00	990	0	8,239	Feb 29 05:01 PM
Khattar Jack A.	President, CEO	Feb 28 '24	Option Exercise	0.00	35,000	0	932,005	Feb 29 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Feb 26 '24	Option Exercise	9.13	5,000	45,650	13,570	Feb 28 05:01 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Feb 26 '24	Sale	30.21	5,000	151,050	8,570	Feb 28 05:01 PM
Martin Tami Tillotson	Sr. V.P., Regulatory Affairs	Jan 10 '24	Option Exercise	9.24	8,000	73,920	93,664	Jan 12 05:00 PM
Martin Tami Tillotson	Sr. V.P., Regulatory Affairs	Jan 10 '24	Sale	27.91	8,000	223,280	85,664	Jan 12 05:00 PM
Rubin Jonathan	Sr. VP, Chief Medical Officer	Dec 22 '23	Option Exercise	0.00	600	0	3,447	Dec 26 05:01 PM
Khattar Jack A.	President, CEO	Dec 22 '23	Option Exercise	0.00	25,000	0	892,463	Dec 26 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Supernus Pharmaceuticals Inc

Upgrade your FINVIZ experience